Home/Filings/4/0001127602-22-024626
4//SEC Filing

DeLuca Richard R. 4

Accession 0001127602-22-024626

CIK 0000310158other

Filed

Oct 31, 8:00 PM ET

Accepted

Nov 1, 5:04 PM ET

Size

14.1 KB

Accession

0001127602-22-024626

Insider Transaction Report

Form 4
Period: 2022-10-28
DeLuca Richard R.
EVP&Pres, Merck Animal Health
Transactions
  • Exercise/Conversion

    Common Stock

    2022-10-28+59,564196,541.143 total
  • Exercise/Conversion

    Common Stock

    2022-10-28+104,993301,534.143 total
  • Sale

    Common Stock

    2022-10-28$100.26/sh164,557$16,499,094136,977.143 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-10-2859,5640 total
    Exercise: $58.08From: 2016-05-01Exp: 2025-04-30Common Stock (59,564 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-10-28104,9930 total
    Exercise: $53.06From: 2017-05-10Exp: 2026-05-09Common Stock (104,993 underlying)
Holdings
  • Common Stock - 401(k) Plan

    (indirect: By 401(k))
    1,192.739
Footnotes (6)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.9100 to $100.5700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
  • [F2]Holdings include shares acquired in dividend reinvestment transactions.
  • [F3]Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
  • [F4]The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
  • [F5]Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
  • [F6]The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

Issuer

Merck & Co., Inc.

CIK 0000310158

Entity typeother

Related Parties

1
  • filerCIK 0001421339

Filing Metadata

Form type
4
Filed
Oct 31, 8:00 PM ET
Accepted
Nov 1, 5:04 PM ET
Size
14.1 KB